1047023-77-7

Basic information

• Product Name: ethyl 1-(4-(4-fluorobenzyl)-4H-thieno[3,2-b]pyrrole-5-carbonyl)-piperidine-4-carboxylate
• Synonyms: ethyl 1-(4-(4-fluorobenzyl)-4H-thieno[3,2-b]pyrrole-5-carbonyl)-piperidine-4-carboxylate
• CAS NO: 1047023-77-7
• Molecular Weight: 414.501
• Mol File: 1047023-77-7.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: ethyl 1-(4-(4-fluorobenzyl)-4H-thieno[3,2-b]pyrrole-5-carbonyl)-piperidine-4-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: ethyl 1-(4-(4-fluorobenzyl)-4H-thieno[3,2-b]pyrrole-5-carbonyl)-piperidine-4-carboxylate(1047023-77-7)
• EPA Substance Registry System: ethyl 1-(4-(4-fluorobenzyl)-4H-thieno[3,2-b]pyrrole-5-carbonyl)-piperidine-4-carboxylate(1047023-77-7)

Safety Data

• Hazardous Substances Data: 1047023-77-7(Hazardous Substances Data)

Upstream product

• 98-03-3 thiophene-2-carbaldehyde 
• 1126-09-6 4-carbethoxypiperidine 
• 897774-27-5 C₁₄H₁₀FNO₂S 
• 82782-85-2 thieno<3,2-b>pyrrole-5-carboxylic acid methyl ester 
• 439113-19-6 methyl 2-azido-3-(thiophen-2-yl)acrylate 
• 897767-45-2 methyl N-(4-fluoro)benzyl-4H-thieno[3,2-b]pyrrole carboxylate 
• 352-11-4 1-chloromethyl-4-fluorobenzene 
• 39793-31-2 4H-thieno[3,2-b]pyrrole-5-carboxylic acid 

Downstream Products

• 1163132-87-3 [4-(4-Fluorobenzyl)-4H-thieno[3,2-b]pyrrol-5-yl][4-(morpholine-4-carbonyl)piperidin-1-yl]methanone 
• 903165-55-9 C₂₀H₁₉FN₂O₃S 
• 902901-29-5 N-benzyl-1-(4-(4-fluorobenzyl)-4H-thieno[3,2-b]pyrrole-5-carbonyl)piperidine-4-carboxamide 

Relevant articles and documents

Novel inhibitors of neurotropic alphavirus replication that improve host survival in a mouse model of acute viral encephalitis

Arboviral encephalitis is a potentially devastating human disease with no approved therapies that target virus replication. We previously discovered a novel class of thieno[3,2-b]pyrrole-based inhibitors active against neurotropic alphaviruses such as western equine encephalitis virus (WEEV) in cultured cells. In this report, we describe initial development of these novel antiviral compounds, including bioisosteric replacement of the 4H-thieno[3,2-b]pyrrole core with indole to improve metabolic stability and the introduction of chirality to assess target enantioselectivity. Selected modifications enhanced antiviral activity while maintaining low cytotoxicity, increased stability to microsomal metabolism, and also revealed striking enantiospecific activity in cultured cells. Furthermore, we demonstrate improved outcomes (both symptoms and survival) following treatment with indole analogue 9h (CCG-203926) in an in vivo mouse model of alphaviral encephalitis that closely correlate with the enantiospecific in vitro antiviral activity. These results represent a substantial advancement in the early preclinical development of a promising class of novel antiviral drugs against virulent neurotropic alphaviruses.